Navigation Links
A Novel Oral Anticoagulant is Planned to be Developed for Patients with Prosthetic Heart Valves or Chronic Renal Dysfunction
Date:3/8/2013

ation therapy is difficult to manage well, even if closely monitored, particularly if they take medicines or foods that affect these enzymes.  Recent data shows that these drug metabolizing enzymes are down regulated in patients with chronic renal dysfunction or failure which may explain the sub-optimal anti-coagulation control with warfarin or with the novel non-monitored OACs in these patients.

Monitoring the effectiveness of warfarin in many cases requires patients to travel frequently to a local clinic to have their anticoagulation status checked and, if needed, doses adjusted.  Recently, perhaps due to reimbursement by healthcare providers, there has been an increase in patient self-monitoring and management of anticoagulation therapy that is currently only applicable to VKOR inhibitors such as tecarfarin. Ultimately, this system could provide many patients with a cost-effective management of anticoagulation therapy with a better patient compliance than with new oral non-monitored OACs.

About Tecarfarin

Tecarfarin (ATI-5923) is potentially a best-in-class orally active vitamin K epoxide (VKOR) inhibitor that was specifically designed to avoid CYP2C9 dependent metabolism and to avoid transport by P-gp. This may mean tecarfarin will need less monitoring than warfarin, potentially resulting in better patient compliance if used together with widely available self-monitoring systems. Unlike the novel non-monitored OACs, tecarfarin has an antidote, vitamin K that is readily available and can be used to rapidly reverse the anticoagulation effect of tecarfarin in an emergency. If approved, tecarfarin could become a superior anticoagulation management solution to warfarin.

About Armetheon

Armetheon, Inc. is a privately held San Francisco Bay area based clinical stage biopharmaceutical company focused on the development of novel drugs for highly unmet need. The company has 3 programs in mid - to late - clinical stage developm
'/>"/>

SOURCE Armetheon, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
3. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
4. Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat
5. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
8. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
9. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
10. OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers
11. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... CHICAGO, Ill. , Sept. 22, 2014 /PRNewswire/ ... data from several clinical studies evaluating potential new ... presented at the upcoming 2014 European Society of ... Madrid, Spain . Data being ... evaluating the safety and efficacy of veliparib (ABT-888), ...
(Date:9/22/2014)... DIEGO , Sept. 22, 2014 Arena Pharmaceuticals, ... company is scheduled to present a corporate overview and ... on Friday, September 26, 2014, at 11:30 a.m. Eastern ... Hotel in New York City . ... will be available under the investor relations section of ...
(Date:9/22/2014)... , September 22, 2014 ... Line Development Market by Product (Equipment, Media and Reagents), ... Engineering & Regenerative medicine, Toxicity Testing, Research, Drug ... published by MarketsandMarkets, analyzes and studies the major ... Browse 114 market data tables and 64 ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
... YORK, Jan. 16, 2012 Reportlinker.com announces ... available in its catalogue: , ... http://www.reportlinker.com/p0751763/Global-Diagnostic-Imaging-Market-Trends-and-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging ... imaging market, including: , Estimates ...
... 13, 2012  MedAssurant, Inc., a leading provider of ... for Quality Assurance (NCQA) Software Certification of its ... Data and Information Set (HEDIS®) measurement and reporting ... use, QSI is the nation,s most widely used ...
Cached Medicine Technology:Global Diagnostic Imaging Market Trends and Outlook 2MedAssurant Earns 2012 NCQA Software Certification 2
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) McMaster scientists have ... a new class of antibiotics. , Although dozens ... looked at how a certain part of bacteria are ... stopping it. , The discovery is important as ... is making the cures for infections ineffective. The World ...
(Date:9/22/2014)... PA (PRWEB) September 22, 2014 An ... for patients to the problem of side-sleeping. "My lower ... side, so I designed a solution to this problem," ... asleep comfortably than to have your arm 'fall asleep.'" ... on his or her side more comfortably. It avoids ...
(Date:9/22/2014)... approaches to reducing poverty that help children and ... advocates, and foundations. By combining education and training ... jobs that offer a path out of poverty ... these programs aim to improve the life opportunities ... report from the National Center for Children in ...
(Date:9/22/2014)... September 22, 2014. Kessler researchers have published a ... psychoeducational wellness program in people with multiple sclerosis ... mental health, perceived stress, and pain. "Development ... individuals living with MS: Description and outcomes" was ... the International Journal of MS Care ...
(Date:9/22/2014)... Va. (PRWEB) September 22, 2014 ... the nation’s leading nonprofit authority on the ... healthcare information exchange, announced findings from its recent ... Health Plan Identifier (HPID) within electronic transactions adopted ... (HIPAA). WEDI conducted the survey from August 20 ...
Breaking Medicine News(10 mins):Health News:A two-generation lens: Current state policies fail to support families with young children 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3
... FRIDAY, July 29 (HealthDay News) -- The brains of ... signs of a brain disease associated with concussions, say ... findings revealed that Bobby Kuntz (of the Toronto Argonauts ... Rough Riders) had chronic traumatic encephalopathy (CTE). Both players ...
... is available in Spanish . Patients suffering ... attacked and pursued, with the particularity that they express them ... Neurology has published the third consecutive work in five ... The first work showed in 2006 that 45% ...
... FRIDAY, July 29 (HealthDay News) -- Developed countries have ... recent years, but a new international study suggests this ... about the availability of increasingly effective treatments and improving ... of World Health Organization (WHO) breast cancer data collected ...
... University of Cincinnati (UC) research on HIV testing at local ... who do not know they are infected with HIV, even ... study is part of a special supplement to the July ... the Centers for Disease Control and Prevention (CDC). The supplement ...
... Neuroscientists at the University of Bristol have received a ... Council (MRC) to continue their research into the pathological ... dementia, affecting around 465,000 people in the UK. ... latest research into how aspects of electrical signalling go ...
... WASHINGTON The U.S. Food and Drug Administration should gather ... replace the 35-year-old 510(k) clearance process for medical devices, says ... 510(k) process lacks the legal basis to be a reliable ... II devices and cannot be transformed into one, concluded the ...
Cached Medicine News:Health News:Concussion Project Finds Disease in Two Autopsied Brains 2Health News:REM sleep behavior disorder is a risk factor for Parkinson's disease 2Health News:Drop in Breast Cancer Death Rates May Not Be Linked to Screening Rates 2Health News:Drop in Breast Cancer Death Rates May Not Be Linked to Screening Rates 3Health News:Study shows missed opportunities for HIV diagnosis in emergency departments 2Health News:Study shows missed opportunities for HIV diagnosis in emergency departments 3Health News:Scientists receive funding boost to further research into disease mechanisms of Alzheimer’s 2Health News:FDA should invest in developing a new regulatory framework to replace flawed 510(k) medical device clearance process 2Health News:FDA should invest in developing a new regulatory framework to replace flawed 510(k) medical device clearance process 3
High resolution, multi-frequency, HST version of the UST-987-7.5. Provides even greater image detail, better resolution, and penetration....
A rigid version of the popular flexible laparoscopic transducer. It has been proven that a rigid "lap transducer has great utility in the OR for being an extra lifting tool inside the abdomen....
This is a 3D transducer for endovaginal imaging in OB/GYN....
Super High Density, 120 field of view, angled handle, multi-frequency, convex endovaginal transducer....
Medicine Products: